Translational strategies in peripheral neuroinflammation and neurovascular repair

Translational Neuroscience

Volumn 3, Issue 4, 2012, Pages 373-383

  Ubogu, Eroboghene E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Blood nerve barrier; Chronic inflammatory demyelinating polyradiculoneuropathy; Endothelial cells; Guillain Barr syndrome; Mouse models; Neuroinflammation; Peripheral nerve; Regeneration

Indexed keywords

CD11B ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN; INTEGRIN; INTEGRIN MONOCLONAL ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN; NATALIZUMAB; PERTUSSIS TOXIN; RANTES; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIGEN EXPRESSION; BLOOD NERVE BARRIER; CELL INTERACTION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DEMYELINATION; DIABETIC NEUROPATHY; DISEASE MODEL; DRUG RESEARCH; ENDONEURIUM; ENDOTHELIUM CELL; GUILLAIN BARRE SYNDROME; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; LEUKOCYTE; MEDICAL RESEARCH; MICROVASCULATURE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NERVE FUNCTION; NERVE REGENERATION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NERVOUS SYSTEM INFLAMMATION; NEURITIS; NEUROBIOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TIGHT JUNCTION;

EID: 84871456626     PISSN: 20813856     EISSN: 20816936     Source Type: Journal    
DOI: 10.2478/s13380-012-0039-4     Document Type: Review

References (75)

1. Bennett G., Neuropathic pain: new insights, new interventions, Hosp. Pract. (Minneap.), 1998, 33, 95-98, 101-104, 107-110 passim
2. Moalem G.,Tracey D., Immune and inflammatory mechanisms in neuropathic pain, Brain Res. Rev., 2006, 51, 240-264
3. White F. A., Jung H., Miller R. J., Chemokines and the pathophysiology of neuropathic pain, Proc. Natl. Acad. Sci. USA, 2007, 104, 20151-20158
4. Dworkin R., An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms, Clin. J. Pain, 2002, 18, 343-349 (Pubitemid 35291574)
5. Kieseier B., Kiefer R., Gold R., Hemmer B., Willison H.,Hartung H., Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system, Muscle Nerve, 2004, 30, 131-156 (Pubitemid 38982218)
6. Meyer zu Hörste G., Hartung H., Kieseier B., From bench to bedside - experimental rationale for immune-specific therapies in the inflamed peripheral nerve, Nat. Clin. Pract. Neurol., 2007, 3, 198-211 (Pubitemid 46605271)
7. McCarberg B. H., Billington R., Consequences of neuropathic pain: quality-of-life issues and associated costs, Am. J. Manag. Care, 2006, 12, S263-268 (Pubitemid 43993104)
8. Hartung H., Willison H., Kieseier B., Acute immunoinflammatory neuropathy: update on Guillain-Barré syndrome, Curr. Opin. Neurol., 2002, 15, 571-577 (Pubitemid 35176692)
9. Hughes R., Cornblath D., Guillain-Barré syndrome, Lancet, 2005, 366, 1653-1666
10. Kieseier B., Kiefer R., Gold R., Hemmer B., Willison H., Hartung H., Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system, Muscle Nerve, 2004, 30, 131-156 (Pubitemid 38982218)
11. Teitelbaum J.S., Borel C.O., Respiratory dysfunction in Guillain-Barré syndrome, Clin. Chest Med., 1994, 15, 705-714
12. Orlikowski D., Prigent H., Sharshar T., Lofaso F., Raphael J. C., Respiratory dysfunction in Guillain-Barré Syndrome, Neurocrit. Care, 2004, 1, 415-422
13. Frenzen P., Economic cost of Guillain-Barré syndrome in the United States, Neurology, 2008, 71, 21-27
14. Meyer zu Hörste G., Hartung H., Kieseier B., From bench to bedside - experimental rationale for immune-specific therapies in the inflamed peripheral nerve, Nat. Clin. Pract. Neurol., 2007, 3, 198-211 (Pubitemid 46605271)
15. Kieseier B., Dalakas M., Hartung H., Immune mechanisms in chronic inflammatory demyelinating neuropathy, Neurology, 2002, 59, S7-12 (Pubitemid 36076543)
16. Chia L., Fernandez A., Lacroix C., Adams D., Planté V., Said G., Contribution of nerve biopsy findings to the diagnosis of disabling neuropathy in the elderly. A retrospective review of 100 consecutive patients, Brain, 1996, 119, 1091-1098 (Pubitemid 26300711)
17. Bouchard C., Lacroix C., Planté V., Adams D., Chedru F., Guglielmi J., et al., Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy, Neurology, 1999, 52, 498-503 (Pubitemid 29075593)
18. Rizzuto N., Morbin M., Cavallaro T., Ferrari S., Fallahi M.,Galiazzo Rizzuto S., Focal lesions area feature of chronic inflammatory demyelinating polyneuropathy (CIDP), Acta Neuropathol., 1998, 96, 603-609 (Pubitemid 28517654)
19. Reina M., López A., Villanueva M., de Andrés J., León G., Morphology of peripheral nerves, their sheaths, and their vascularization, Rev. Esp. Anestesiol. Reanim., 2000, 47, 464-475 (Pubitemid 33616851)
20. Reina M., López A., Villanueva M., De Andrés J., Machés F., The bloodnerve barrier in peripheral nerves, Rev. Esp. Anestesiol. Reanim., 2003, 50, 80-86
21. Olsson Y., Studies on vascular permeability in peripheral nerves. I. Distribution of circulating fluorescent serum albumin in normal, crushed and sectioned rat sciatic nerve, Acta Neuropathol., 1966, 7, 1-15
22. Olsson Y., Topographical differences in the vascular permeability of the peripheral nervous system, Acta Neuropathol., 1968, 10, 26-33
23. Olsson Y., Microenvironment of the peripheral nervous system under normal and pathological conditions, Crit. Rev. Neurobiol., 1990, 5, 265-311 (Pubitemid 20128523)
24. Olsson Y., Studies on vascular permeability in peripheral nerves. IV. Distribution of intravenously injected protein tracers in the peripheral nervous system of various species, Acta Neuropathol., 1971, 17, 114-126
25. Hultström D., Malmgren L., Gilstring D.,Olsson Y., FITC-Dextrans as tracers for macromolecular movements in the nervous system. A freeze-drying method for dextrans of various molecular sizes injected into normal animals, Acta Neuropathol., 1983, 59, 53-62 (Pubitemid 13174429)
26. Malmgren L.,Olsson Y., Differences between the peripheral and the central nervous system in permeability to sodium fluorescein, J. Comp. Neurol., 1980, 191, 103-107
27. Poduslo J., Curran G., Berg C., Macromolecular permeability across the blood-nerve and blood-brain barriers, Proc. Natl. Acad. Sci. USA, 1994, 91, 5705-5709 (Pubitemid 24174397)
28. Huebner E., Strittmatter S., Axon regeneration in the peripheral and central nervous systems, Results Probl. Cell Differ., 2009, 48, 339-351
29. Scherer S., The biology and pathobiology of Schwann cells, Curr. Opin. Neurol., 1997, 10, 386-397 (Pubitemid 27445627)
30. Höke A., Mi R., In search of novel treatments for peripheral neuropathies and nerve regeneration, Discov. Med., 2007, 7, 109-112
31. Chen Z., Yu W., Strickland S., Peripheral regeneration, Annu. Rev. Neurosci., 2007, 30, 209-233 (Pubitemid 47218756)
32. Poduslo J., Curran G., Dyck P., Increase in albumin, IgG, and IgM blood-nerve barrier indices in human diabetic neuropathy, Proc. Natl. Acad. Sci. USA, 1988, 85, 4879-4883
33. Giannini C., Dyck P., Ultrastructural morphometric abnormalities of sural nerve endoneurial microvessels in diabetes mellitus, Ann. Neurol., 1994, 36, 408-415 (Pubitemid 24280062)
34. Malik R., Newrick P., Sharma A., Jennings A., Ah-See A., Mayhew T., et al., Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy, Diabetologia, 1989, 32, 92-102 (Pubitemid 19096380)
35. Malik R., Veves A., Masson E., Sharma A., Ah-See A., Schady W., et al., Endoneurial capillary abnormalities in mild human diabetic neuropathy, J. Neurol. Neurosurg. Psychiatry, 1992, 55, 557-561
36. Ubogu E. E., Yosef N., Xia R. H., Sheikh K. A., Behavioral, electrophysiological, and histopathological characterization of a severe murine chronic demyelinating polyneuritis model, J. Peripher. Nerv. Syst., 2012, 17, 53-61
37. Xia R., Yosef N., Ubogu E., Clinical, electrophysiological and pathologic correlations in a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome, J. Neuroimmunol., 2010, 219, 54-63
38. Yosef N., Xia R., Ubogu E., Development and characterization of a novel human in vitro blood-nerve barrier model using primary endoneurial endothelial cells, J. Neuropathol. Exp. Neurol., 2010, 69, 82-97
39. Calida D., Kremlev S., Fujioka T., Hilliard B., Ventura E., Constantinescu C., et al., Experimental allergic neuritis in the SJL/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12, J. Neuroimmunol., 2000, 107, 1-7 (Pubitemid 30243125)
40. Kieseier B., Tani M., Mahad D., Oka N., Ho T., Woodroofe N., et al., Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10, Brain, 2002, 125, 823-834 (Pubitemid 34279777)
41. Lu M.O., Zhu J., The role of cytokines in Guillain-Barré syndrome, J. Neurol., 2011, 258, 533-548
42. Orlikowski D., Chazaud B., Plonquet A., Poron F., Sharshar T., Maison P., et al., Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain-Barré syndrome and experimental autoimmune neuritis, J. Neuroimmunol., 2003, 134, 118-127 (Pubitemid 36050837)
43. Press R., Pashenkov M., Jin J., Link H., Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy, J. Clin. Immunol., 2003, 23, 259-267 (Pubitemid 36870668)
44. Xia R. H., Yosef N., Ubogu E. E., Selective expression and cellular localization of pro-inflammatory chemokine ligand/receptor pairs in the sciatic nerves of a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome, Neuropathol. Appl. Neurobiol., 2010, 36, 388-398
45. Ubogu E., Cossoy M., Ransohoff R., The expression and function of chemokines involved in CNS inflammation, Trends Pharmacol. Sci., 2006, 27, 48-55 (Pubitemid 43063124)
46. Ubogu E. E., Chemokine receptors as specific anti-inflammatory targets in peripheral nerves, Endocr. Metab. Immune Disord. Drug Targets, 2011, 11, 141-153
47. Alon R., Ley K., Cells on the run: shear-regulated integrin activation in leukocyte rolling and arrest on endothelial cells, Curr. Opin. Cell Biol., 2008, 20, 525-532
48. Man S., Ubogu E., Ransohoff R., Inflammatory cell migration into the central nervous system: a few new twists on an old tale, Brain Pathol., 2007, 17, 243-250 (Pubitemid 46466143)
49. Yosef N., Ubogu E. E., alpha(M) beta(2) -integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barré syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro, J. Cell Physiol., 2012, 227, 3857-3875
50. Silverman M., Zamora D., Pan Y., Texeira P., Planck S., Rosenbaum J., Cell adhesion molecule expression in cultured human iris endothelial cells, Invest. Ophthalmol. Vis. Sci., 2001, 42, 2861-2866 (Pubitemid 33035284)
51. Bö L., Peterson J., Mørk S., Hoffman P., Gallatin W., Ransohoff R., et al., Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions, J. Neuropathol. Exp. Neurol., 1996, 55, 1060-1072 (Pubitemid 26338018)
52. Ubogu E., Callahan M., Tucky B., Ransohoff R., Determinants of CCL5- driven mononuclear cell migration across the blood-brain barrier. Implications for therapeutically modulating neuroinflammation, J. Neuroimmunol., 2006, 179, 132-144 (Pubitemid 44468129)
53. Salomon B., Rhee L., Bour-Jordan H., Hsin H., Montag A., Soliven B., et al., Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice, J. Exp. Med., 2001, 194, 677-684 (Pubitemid 32844777)
54. Louvet C., Kabre B., Davini D., Martinier N., Su M., DeVoss J., et al., A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy, J. Exp. Med., 2009, 206, 507-514
55. Nagamatsu M., Terao S., Misu K., Li M., Hattori N., Ichimura M., et al., Axonal and perikaryal involvement in chronic inflammatory demyelinating polyneuropathy, J. Neurol. Neurosurg. Psychiatry, 1999, 66, 727-733 (Pubitemid 29245705)
56. Lindenlaub T., Sommer C., Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies, Acta Neuropathol., 2003, 105, 593-602 (Pubitemid 36798860)
57. Putzu G.A., Figarella-Branger D., Bouvier-Labit C., Liprandi A., Bianco N., Pellissier J.F., Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barré syndrome, J. Neurol. Sci., 2000, 174, 16-21 (Pubitemid 30110543)
58. Nishimura N., Schaffer C., Friedman B., Tsai P., Lyden P., Kleinfeld D., Targeted insult to subsurface cortical blood vessels using ultrashort laser pulses: three models of stroke, Nat. Methods, 2006, 3, 99-108 (Pubitemid 43173308)
59. Pereira Lopes F. R., Lisboa B. C., Frattini F., Almeida F. M., Tomaz M. A., Matsumoto P. K., et al., Enhancement of sciatic nerve regeneration after vascular endothelial growth factor (VEGF) gene therapy, Neuropathol. Appl. Neurobiol., 2011, 37, 600-612
60. Pola R., Aprahamian T. R., Bosch-Marce M., Curry C., Gaetani E., Flex A., et al., Age-dependent VEGF expression and intraneural neovascularization during regeneration of peripheral nerves, Neurobiol. Aging, 2004, 25, 1361-1368 (Pubitemid 39299174)
61. Sun Y., Jin K., Xie L., Childs J., Mao X., Logvinova A., et al., VEGFinduced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia, J. Clin. Invest., 2003, 111, 1843-1851 (Pubitemid 38057729)
62. Zachary I., Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential, Neurosignals, 2005, 14, 207-221 (Pubitemid 41661355)
63. Gupta R., Gray M., Chao T., Bear D., Modafferi E., Mozaffar T., Schwann cells upregulate vascular endothelial growth factor secondary to chronic nerve compression injury, Muscle Nerve, 2005, 31, 452-460 (Pubitemid 40393089)
64. Yosef N., Ubogu E. E., GDNF restores human blood-nerve barrier function via RET tyrosine kinase-mediated cytoskeletal reorganization, Microvasc. Res., 2012, 83, 298-310
65. Shen W., Li S., Chung S. H., Zhu L., Stayt J., Su T., et al., Tyrosine phosphorylation of VE-cadherin and claudin-5 is associated with TGF-beta1-induced permeability of centrally derived vascular endothelium, Eur. J. Cell Biol., 2011, 90, 323-332
66. Bär K. J., Saldanha G. J., Kennedy A. J., Facer P., Birch R., Carlstedt T., et al., GDNF and its receptor component Ret in injured human nerves and dorsal root ganglia., Neuroreport, 1998, 9, 43-47 (Pubitemid 28046651)
67. Beck K. D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R. A., et al., Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain, Nature, 1995, 373, 339-341
68. Bennett D. L., Michael G. J., Ramachandran N., Munson J. B., Averill S., Yan Q., et al., A distinct subgroup of small DRG cells express GDNF receptor components and GDNF is protective for these neurons after nerve injury, J. Neurosci., 1998, 18, 3059-3072 (Pubitemid 28163236)
69. Boyd J. G., Gordon T., Glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor sustain the axonal regeneration of chronically axotomized motoneurons in vivo, Exp. Neurol., 2003, 183, 610-619 (Pubitemid 37205103)
70. Hammarberg H., Piehl F., Cullheim S., Fjell J., Hökfelt T., Fried K., GDNF mRNA in Schwann cells and DRG satellite cells after chronic sciatic nerve injury, Neuroreport, 1996, 7, 857-860 (Pubitemid 26167964)
71. Henderson C. E., Phillips H. S., Pollock R. A., Davies A. M., Lemeulle C., Armanini M., et al., GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle, Science, 1994, 266, 1062-1064 (Pubitemid 24373728)
72. Pascual A., Hidalgo-Figueroa M., Piruat J. I., Pintado C. O., Gomez- Diaz R., Lopez-Barneo J., Absolute requirement of GDNF for adult catecholaminergic neuron survival, Nat. Neurosci., 2008, 11, 755-761 (Pubitemid 351896676)
73. Shi J. Y., Liu G. S., Liu L. F., Kuo S. M., Ton C. H., Wen Z. H., et al., Glial cell line-derived neurotrophic factor gene transfer exerts protective effect on axons in sciatic nerve following constriction-induced peripheral nerve injury, Hum. Gene Ther., 2011, 22, 721-731
74. Springer J. E., Seeburger J. L., He J., Gabrea A., Blankenhorn E. P., Bergman L. W., cDNA sequence and differential mRNA regulation of two forms of glial cell line-derived neurotrophic factor in Schwann cells and rat skeletal muscle, Exp. Neurol., 1995, 131, 47-52
75. Ropper A. H., Gorson K. C., Gooch C. L., Weinberg D. H., Pieczek A., Ware J. H., et al., Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial, Ann. Neurol., 2009, 65, 386-393